CNS drugs · 2026
Tenecteplase Beyond the 4.5-h Window for Patients with Acute Ischemic Stroke: An Updated Meta-Analysis of Randomized Controlled Trials.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gonçalves Ocílio Ribeiro, Scarcia Luca, Portela João Gabriel Silva, Santos Gabriel Soares Bruno, Cardoso Leonardo Januario Campos, da Silva Anderson Matheus Pereira, de Melo Neto Altair Pereira, Sanders João Victor, Falcão Luciano, de Bastos Maximiano Mariana Letícia, Porto Luis Felipe Vieira Nunes, Clarençon Frédéric, Nguyen Thanh, Almeida Kelson James, Günkan Ahmet
Аннотация
INTRODUCTION: Intravenous thrombolysis (IVT) is the established treatment for acute ischemic stroke (AIS) when administered within 4.5 h of the last known well (LKW) status. However, this narrow therapeutic window limits the number of patients eligible for treatment. In this context, tenecteplase (TNK) is being investigated as an alternative thrombolytic agent in the extended time window.
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of intravenous TNK in patients with AIS treated in the extended time window (beyond 4.5 h from LKW) compared with best medical treatment (BMT) without IVT.
METHODS: We conducted a systematic literature review and meta-analysis of patients with AIS presenting beyond 4.5 h from LKW treated with TNK or BMT in randomized controlled trials (RCTs). The safety outcomes included: (1) symptomatic intracranial hemorrhage (sICH), (2) mortality at 90 days, (3) any intracranial hemorrhage (ICH), and (4) parenchymal hemorrhage type 2 (PH2). The efficacy outcomes included: (1) excellent functional outcome (modified Rankin scale [mRS] 0-1) at 90 days, (2) functional independence (mRS 0-2) at 90 days, and (3) early neurological improvement. An analysis based on odds ratios (OR) with 95% confidence intervals (CI) under a random-effects model was used for data pooling. Heterogeneity was assessed using the Q test and its P-value, with the magnitude evaluated by I2 values.
RESULTS: A total of 6 RCTs including 2297 patients were analyzed, with 1152 patients receiving TNK and 1145 receiving BMT. Compared with BMT, TNK administered in the extended time window was associated with significantly higher rates of excellent functional outcomes (mRS 0-1: OR 1.40, 95% CI 1.18-1.67; P < 0.001), functional independence (mRS 0-2: OR 1.27, 95% CI 1.07-1.51; P = 0.006), and early neurological improvement (OR 3.21, 95% CI 1.82-5.66; P < 0.001). TNK was associated with a significant increase in sICH (OR 2.34, 95% CI 1.11-4.95; P = 0.026). No significant differences were observed in 90-day mortality (OR 1.17, 95% CI 0.89-1.55), any ICH (OR 1.61, 95% CI 0.37-6.95), or PH2 (OR 1.81, 95% CI 0.90-3.64).
CONCLUSIONS: In patients with AIS treated beyond 4.5 h from symptom onset, intravenous TNK significantly improves functional outcomes and early neurological recovery compared with BMT, without a significant increase in mortality. Although sICH was significantly increased, absolute rates remained low. These findings support the potential role of tenecteplase as an effective thrombolytic option in the extended time window for carefully selected patients.
REGISTRATION: PROSPERO identifier no. CRD420251060492.
OBJECTIVE: The objective of this study was to evaluate the safety and efficacy of intravenous TNK in patients with AIS treated in the extended time window (beyond 4.5 h from LKW) compared with best medical treatment (BMT) without IVT.
METHODS: We conducted a systematic literature review and meta-analysis of patients with AIS presenting beyond 4.5 h from LKW treated with TNK or BMT in randomized controlled trials (RCTs). The safety outcomes included: (1) symptomatic intracranial hemorrhage (sICH), (2) mortality at 90 days, (3) any intracranial hemorrhage (ICH), and (4) parenchymal hemorrhage type 2 (PH2). The efficacy outcomes included: (1) excellent functional outcome (modified Rankin scale [mRS] 0-1) at 90 days, (2) functional independence (mRS 0-2) at 90 days, and (3) early neurological improvement. An analysis based on odds ratios (OR) with 95% confidence intervals (CI) under a random-effects model was used for data pooling. Heterogeneity was assessed using the Q test and its P-value, with the magnitude evaluated by I2 values.
RESULTS: A total of 6 RCTs including 2297 patients were analyzed, with 1152 patients receiving TNK and 1145 receiving BMT. Compared with BMT, TNK administered in the extended time window was associated with significantly higher rates of excellent functional outcomes (mRS 0-1: OR 1.40, 95% CI 1.18-1.67; P < 0.001), functional independence (mRS 0-2: OR 1.27, 95% CI 1.07-1.51; P = 0.006), and early neurological improvement (OR 3.21, 95% CI 1.82-5.66; P < 0.001). TNK was associated with a significant increase in sICH (OR 2.34, 95% CI 1.11-4.95; P = 0.026). No significant differences were observed in 90-day mortality (OR 1.17, 95% CI 0.89-1.55), any ICH (OR 1.61, 95% CI 0.37-6.95), or PH2 (OR 1.81, 95% CI 0.90-3.64).
CONCLUSIONS: In patients with AIS treated beyond 4.5 h from symptom onset, intravenous TNK significantly improves functional outcomes and early neurological recovery compared with BMT, without a significant increase in mortality. Although sICH was significantly increased, absolute rates remained low. These findings support the potential role of tenecteplase as an effective thrombolytic option in the extended time window for carefully selected patients.
REGISTRATION: PROSPERO identifier no. CRD420251060492.